Pfizer-BioNTech COVID vaccine causes mostly mild side effects in children aged 5 to 11 years, says USCDC

Published On 2022-01-02 04:30 GMT   |   Update On 2024-02-21 05:59 GMT

New Delhi: Pfizer Inc and BioNTech SE's COVID-19 vaccine caused mostly mild side effects in children aged 5 to 11 years, according to data published by the U.S. Centers for Disease Control and Prevention on Thursday.The data showed that after the second dose of the vaccine some children reported injection-site pain and other systemic reactions such as fatigue and headache.The CDC said it...

Login or Register to read the full article

New Delhi: Pfizer Inc and BioNTech SE's COVID-19 vaccine caused mostly mild side effects in children aged 5 to 11 years, according to data published by the U.S. Centers for Disease Control and Prevention on Thursday.

The data showed that after the second dose of the vaccine some children reported injection-site pain and other systemic reactions such as fatigue and headache.

The CDC said it also received reports of 11 cases of myocarditis, a type of heart inflammation, in children aged 5-11 years who had received the vaccine. Of them, seven had recovered, and four were recovering at the time of the report.

Myocarditis is a rare side effect after mRNA vaccines.

U.S. Vaccine Adverse Event Reporting System (VAERS) received 4,249 reports of adverse events, of which 97.6% of the cases were not serious, the CDC report said.

The cases were reported in VAERS and v-safe, a voluntary smartphone-based safety surveillance system for adverse events after COVID-19 vaccination, between Nov. 3 and Dec. 19.

The agency said about 8.7 million doses of the Pfizer vaccine had been administered to children in the age group.

The vaccine was authorized in the United States for 5 to 15-year-olds in late October and is the only shot authorized for the age group.

Read also: Updated jab in response to Omicron variant could be ready in 100 days: Pfizer CEO

A separate study by the CDC showed that Pfizer's two-dose vaccine was 92% effective against coronavirus infections in adolescents aged 12 to 17.

The observation period for the analysis coincided with the period of Delta variant predominance in the United States, CDC said.

Read also: Pfizer, BioNTech seek USFDA approval for COMIRNATY in adolescents aged 12-15 years

Tags:    
Article Source : Reuters

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News